Skip to main content
Create Account
Training Center
Contact Us
Questions? Comments?
Contact us.
Email:
PLUS@pli.edu
Phone:
877.900.5291
PLI.edu
SIGN IN
Search
Browse
All Content
Books
- Answer Books
- Course Handbooks
- Journals
- Insights
- Treatises
Forms & Checklists
Transcripts
My Bookshelf
My History
< Back To Results
1 in 1 results
Previous Result
Next Result
Health Care Law Institute 2016: Emerging Challenges and Trends in Reimbursement, Enforcement, Compliance and other Hot Topics
Chair(s):
David J. Farber, Esther Scherb
Practice Area:
Enforcement (Health care),
Health care,
Health insurance,
Insurance,
Insurance products,
Regulation and compliance (Health care)
Published:
Dec 2016
i
Other versions can be found in the
Related Items
tab.
ISBN:
9781402428043
PLI Item #:
151074
CHB Spine #:
M12
This version is not current.
Click here for the most recent version.
Search
Email
Print
Add To Bookshelf
Permalink
Table of Contents
Related Items
Select All
Front Matter
Faculty Bios
Table of Contents
Chapter 1. First Year in Review: Top Ten Things to Know about Biosimilar Reimbursement in the U.S. (April 14, 2016)
Chapter 2. Medicare Part B Drug Payments Implicated in CMMI Models
Chapter 3. Proposed Medicare Part B Rule Would Reduce Payments to Hospitals and Some Specialists, While Increasing Payments to Primary Care Providers (April 7, 2016)
Chapter 4. Commercial Uncertainty Remains as U.S. Biosimilar Pipeline Matures
Chapter 5. Health Plans Are Interested in Tying Drug Payments to Patient Outcomes (June 16, 2016)
Chapter 6. Medicare Beneficiaries Will Pay More for Biosimilars than for Their Biologic Reference Products in Part D (April 12, 2016)
Chapter 7. CMS Plans to Overhaul Medicares Beneficiary Identification System: What You Need to Know (October 13, 2016)
Chapter 8. Sweeping Changes in Store for Laboratory Payments: Medicare Sets Rule for Market Rates Starting in 2018 (July 6, 2016)
Chapter 9. CMS Finalizes Medicare Laboratory Payment Overhaul (June 2016)
Chapter 10. Amarin and FDA Agree to Landmark Settlement on Off-Label Promotion (March 2016)
Chapter 11. Supreme Court Decides Validity of Implied False Certification Theory in Universal Health Services v. Escobar (June 2016)
Chapter 12. General Memo: Individual Accountability for Corporate Wrongdoing, Sally Quillian Yates, Deputy Attorney General (September 9, 2015)
Chapter 13. 2016 Mid-Year FDA and Health Care Compliance and Enforcement Update—Drugs and Devices (July 27, 2016)
Chapter 14. CMS Abandons Payment Cut Imposed By Two-Midnight Rule (April 20, 2016)
Chapter 15. Supreme Court Holds Providers Cannot Sue States to Challenge Low Medicaid Rates (April 3, 2015)
Chapter 16. The Dynamic Political and Public Policy Landscape in DC on Pharmaceutical Issues (October 11, 2016)
Chapter 17. Medicare Program; Merit-based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentive under the Physician Fee Schedule, and Criteria for Physician-Focused Payment Models (October 14, 2016)
Chapter 18. Medicare Access and CHIP Reauthorization Act of 2015, Pub. Law 114–10 (April 16, 2015)
Chapter 19. 21st Century Cures Act, H.R. 6 Section-by-Section Summary, House Committee on Energy & Commerce (July 2, 2015)
Index
About Us